Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , June 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
-- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate,  Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response was 9.2 Months -- NEWTON, Mass. , June 19, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML
Toggle Summary Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dose Dexamethasone Demonstrates 73% ORR in Patients
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Jefferies 2019 Global Healthcare Conference
View HTML
Toggle Summary Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and
View HTML
Toggle Summary Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
-- Dr. Shacham Recognized for Research That Led to the Development of Oral Selinexor and other SINE Compounds -- NEWTON, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief
View HTML
Toggle Summary Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
--  FDA Extends Review Period for Selinexor New Drug Application to July 6 , 2019 -- -- Selinexor MAA Validated in Europe ; Approval Decision Expected by End of 2019 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- NEWTON, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics
View HTML
Toggle Summary Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care
View HTML